Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on April 4, 2019, covering events occurring on March 29, 2019. The Company is an emerging growth company incorporated in Delaware, headquartered in San Francisco, California.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt levels. The only specific financial figure disclosed relates to a letter of credit obligation of $122,000.
Material Changes and Agreements
On March 29, 2019, the Company entered into a Letter of Credit Cancellation and Warrant Issuance Agreement with the beneficiary of a $122,000 standby letter of credit (the "LC Beneficiary"). Key terms include:
- Cancellation: The LC Beneficiary agreed to cancel the $122,000 letter of credit and terminate the Company's reduced exposure obligation.
- Consideration: In exchange, the Company issued a 5-year warrant (the "LOC Warrant") to purchase shares of common stock.
- Warrant Quantity: The number of shares is equal to 75% of the $122,000 principal amount divided by the Exercise Price.
- Exercise Price: Defined as the price per share in the Company's next underwritten public offering. If no public offering occurs within four months of issuance, the price will be the closing sales price on that four-month anniversary.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond the standard terms of the warrant agreement. The issuance of the warrant was made in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D to an accredited investor.
Investor Verification Checklist
- Verify the exact number of shares issuable under the LOC Warrant once the Exercise Price is determined.
- Monitor the Company's progress toward an underwritten public offering to determine if the four-month fallback pricing mechanism will be triggered.
- Review the full text of the Letter of Credit Cancellation & Warrant Issuance Agreement (Exhibit 10.1) for additional covenants or conditions.
- Confirm the current status of the Company's broader capital structure and liquidity position, as this filing does not provide comprehensive financial statements.